Abstract
Purpose
Head and neck squamous cell carcinoma (HNSCC) represents an ideal model for assessing the impact of anemia and tumor hypoxia on the response to radiotherapy (RT). Various treatment strategies aimed at increasing tumor oxygenation in HNSCC patients have been studied and these studies have been fueled by evidence that hypoxia and, unexpectedly, erythropoietin (EPO), adversely affect the radiosensitivity of cells. The purpose of the present study was to experimentally examine the relationship between hypoxia, EPO, its receptor EPOR, EGFR and their effects on the survival and radiosensitivity of HNSCC cells underwent hypoxia.
Methods
We used Cal-166 head and neck cell line to investigate different cellular responses after RT given in oxic and hypoxic conditions, focusing on the role of EPO administration in cell proliferation and in regulating response to RT.
Results
Our results show that EPO do not evoke a physiologic response on EPOR-bearing tumor cells as assessed by cellular growth and proliferation. In addition, we present some indications that EPO could activate opposite signals related to proliferation, DNA repair and apoptosis. Among them, EGFR and AKT phosphorylation may play a role in radioresistance.
Conclusions
We concluded that the expression of the EPOR in Cal-166 cells does not seem essential for their growth and that administration of EPO does not affect RT efficacy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Acs G, Zhang PJ, McGrath CM et al (2003) Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am J Pathol 162:1789–1806
Acs G, Xu X, Chu C, Acs P, Verma A (2004) Prognostic significance of erythropoietin expression in human endometrial carcinoma. Cancer 100:2376–2386. doi:10.1002/cncr.20244
Belenkov AI, Shenouda G, Rizhevskaya E et al (2004) Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin. Mol Cancer Ther 3:1525–1532
Bussink J, van der Kogel AJ, Kaanders JH (2008) Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol 9:288–296. doi:10.1016/S1470-2045(08)70073-1
Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB (1987) Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47:936–942
Cazzola M, Beguin Y, Kloczko J, Spicka I, Coiffier B (2003) Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 122:386–393. doi:10.1046/j.1365-2141.2003.04439.x
Chen J, Jacobs-Helber SM, Barber DL, Sawyer ST (2004) Erythropoietin-dependent autocrine secretion of tumor necrosis factor-alpha in hematopoietic cells modulates proliferation via MAP kinase-ERK-1/2 and does not require tyrosine docking sites in the EPO receptor. Exp Cell Res 298:155–166. doi:10.1016/j.yexcr.2004.04.009
Cohen NA, Lai SY, Ziober AF, Ziober BL (2004) Dysregulation of hypoxia inducible factor-1 alpha in head and neck squamous cell carcinoma cell lines correlates with invasive potential. Laryngoscope 114:418–423. doi:10.1097/00005537-200403000-00006
Dunlop EA, Percy MJ, Boland MP, Maxwell AP, Lappin TR (2006) Induction of signaling in non-erythroid cells by pharmacological levels of erythropoietin. Neurodegener Dis 3:94–100. doi:10.1159/000092099
Ebert BL, Bunn HF (1999) Regulation of the erythropoietin gene. Blood 94:1864–1877
Feldman L, Wang Y, Rhim JS et al (2006) Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells. Prostate 66:135–145. doi:10.1002/pros.20310
Franovic A, Gunaratnam L, Smith K et al (2007) Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer. Proc Natl Acad Sci USA 104:13092–13097. doi:10.1073/pnas.0702387104
Gunaratnam L, Morley M, Franovic A et al (2003) Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(−/−) renal cell carcinoma cells. J Biol Chem 278:44966–44974. doi:10.1074/jbc.M305502200
Haq R, Halupa A, Beattie BK et al (2002) Regulation of erythropoietin-induced STAT serine phosphorylation by distinct mitogen-activated protein kinases. J Biol Chem 277:17359–17366. doi:10.1074/jbc.M201842200
Hedenus M, Adriansson M, San Miguel J et al (2003) Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 122:394–403. doi:10.1046/j.1365-2141.2003.04448.x
Henke M, Laszig R, Rübe C et al (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362:1255–1260. doi:10.1016/S0140-6736(03)14567-9
Henke M, Mattern D, Pepe M et al (2006) Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 24:4708–4713. doi:10.1200/JCO.2006.06.2737
Hennequin C (2006) Erythropoietin and radiation therapy. Bull Cancer 93:495–499
Lacombe C, Mayeux P (1998) Biology of erythropoietin. Haematologica 83:724–732
Laderoute KR, Grant TD, Murphy BJ, Sutherland RM (1992) Enhanced epidermal growth factor receptor synthesis in human squamous carcinoma cells exposed to low levels of oxygen. Int J Cancer 52:428–432. doi:10.1002/ijc.2910520317
LaMontagne KR, Butler J, Marshall DJ et al (2006) Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol Cancer Ther 5:347–355. doi:10.1158/1535-7163.MCT-05-0203
Leyland-Jones B, BEST Investigators and Study Group (2003) Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4:459–460. doi:10.1016/S1470-2045(03)01163-X
Leyland-Jones B, Semiglazov V, Pawlicki M et al (2005) Maintaining normal hemoglobin levels with epoetin α in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23:5960–5972. doi:10.1200/JCO.2005.06.150
Littlewood TJ (2001) The impact of hemoglobin levels on treatment outcomes in patients with cancer. Semin Oncol 28:49–53. doi:10.1016/S0093-7754(01)90213-1
Ludwig H (2004) rHuEPO and treatment outcomes: the preclinical experience. Oncologist 9:48–54. doi:10.1634/theoncologist.9-90005-48
McBroom JW, Acs G, Rose GS et al (2005) Erythropoietin receptor function and expression in epithelial ovarian carcinoma. Gynecol Oncol 99:571–577. doi:10.1016/j.ygyno.2005.06.038
Mendelshon J (2002) Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 20:1s–13s
Nishi H, Nishi KH, Johnson AC (2002) Early growth response-1 gene mediates up-regulation of epidermal growth factor receptor expression during hypoxia. Cancer Res 62:827–834
Pajonk F, Weil A, Sommer A, Suwinski R, Henke M (2004) The erythropoietin-receptor pathway modulates survival of cancer cells. Oncogene 23:8987–8991. doi:10.1038/sj.onc.1208140
Rodemann HP, Dittmann K, Toulany M (2007) Radiation-induced EGFR-signaling and control of DNA-damage repair. Int J Radiat Biol 83:781–791. doi:10.1080/09553000701769970
Rosti V, Pedrazzoli P, Ponchio L et al (1993) Effect of recombinant human erythropoietin on hematopoietic and non-hematopoietic malignant cell growth in vitro. Haematologica 78:208–212
Selzer E, Wacheck V, Kodym R et al (2000) Erythropoietin receptor expression in human melanoma cells. Melanoma Res 10:421–426. doi:10.1097/00008390-200010000-00003
Sinclair AM, Rogers N, Busse L et al (2008) Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells. Br J Cancer 98:1059–1067. doi:10.1038/sj.bjc.6604220
Swinson DE, Jones JL, Cox G et al (2004) Hypoxia-inducible factor-1 alpha in non small cell lung cancer: relation to growth factor, protease and apoptosis pathways. Int J Cancer 111:43–50. doi:10.1002/ijc.20052
Tilbrook PA, Klinken SP (1999) The erythropoietin receptor. Int J Biochem Cell Biol 31:1001–1005. doi:10.1016/S1357-2725(99)00071-0
Toulany M, Dittmann K, Fehrenbacher B et al (2008) PI3 K-Akt signaling regulates basal, but MAP-kinase signaling regulates radiation-induced XRCC1 expression in human tumor cells in vitro. DNA Repair (Amst) 7:1746–1756. doi:10.1016/j.dnarep.2008.06.017
Um M, Gross AW, Lodish HF (2007) A “classical” homodimeric erythropoietin receptor is essential for the antiapoptotic effects of erythropoietin on differentiated neuroblastoma SH-SY5Y and pheochromocytoma PC-12 cells. Cell Signal 19:634–645. doi:10.1016/j.cellsig.2006.08.014
Westenfelder C, Baranowski RL (2000) Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 58:647–657. doi:10.1046/j.1523-1755.2000.00211.x
Witzig TE, Silberstein PT, Loprinzi CL et al (2005) Phase III, randomized, double-blind study of epoetin α compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 23:2606–2617. doi:10.1200/JCO.2004.10.020
Woodburn JR (1999) The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82:241–250. doi:10.1016/S0163-7258(98)00045-X
Zolzer F, Streffer C (2002) Increased radiosensitivity with chronic hypoxia in four human tumor cell lines. Int J Radiat Oncol Biol Phys 54:910–920. doi:10.1016/S0360-3016(02)02963-2
Acknowledgments
This work was partially supported by a Roche Foundation for Anemia Research grant to Merlano M. and Lo Nigro C.
Conflicts of interest statement
On the behalf of all the authors, Dr. Cristiana Lo Nigro explicitly states that any actual or potential conflict of interests does not exist.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lo Nigro, C., Maffi, M., Fischel, J.L. et al. Impact of erythropoietin on the effects of irradiation under hypoxia. J Cancer Res Clin Oncol 135, 1615–1623 (2009). https://doi.org/10.1007/s00432-009-0609-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-009-0609-1